Related Experiment Video
Updated: Jul 2, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
Published on: May 27, 2011
Anti-CD20 Therapy in Children With Severe Epstein-Barr Virus-Associated Meningoencephalitis
Sana Ahsan1, Saba Jafarpour2, Mellad M Khoshnood2
1California University of Science and Medicine, Colton, CA, USA.
None:
Epstein-Barr virus meningoencephalitis is a rare central nervous system infection that lacks standardized treatment. Immunocompetent and immunosuppressed individuals with this condition frequently have poor prognostic outcomes, making the need to identify therapeutic interventions high. Here, we report 2 pediatric cases of severe Epstein-Barr virus meningoencephalitis, both unresponsive to immunoglobulin and corticosteroid therapy, who demonstrated rapid clinical recovery following rituximab administration. Prognostic outcomes revealed marked improvements in symptoms, neurologic function, and quality of life. Rituximab may offer therapeutic potential in severe and refractory Epstein-Barr virus meningoencephalitis through the medication's target of Epstein-Barr virus harboring B cells. This report emphasizes the need for timely evaluation and consideration of rituximab therapy in immunocompetent pediatric patients with Epstein-Barr virus meningoencephalitis.
More Related Videos
09:43An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
Published on: March 30, 2018
08:44Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
Published on: September 7, 2022
Related Concept Videos
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Arboviral Encephalitis
Cytomegalovirus Disease
Respiratory Syncytial Virus Disease
Cryptococcal Meningitis
Encephalitis ll: Pathophysiology